Sartorius Stedim Biotech (CHIX:DIMP) Growth Rank: 7 (As of Aug. 10, 2026) — 30% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
86 GF Score
Price €172.65
GF Value €201.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Growth Rank?

Sartorius Stedim Biotech CHIX:DIMP 86 Growth Rank is 7 as of Aug. 10, 2026, which is 30% below its 10-year median of 10.00. GuruFocus rates CHIX:DIMP with a GF Score™ of 86/100 and a GF Value™ of €201.36 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Sartorius Stedim Biotech has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sartorius Stedim Biotech Growth Rank Related Terms

CHIX:DIMP vs ISRG, BDX, MDLN: Growth Rank Comparison

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius Stedim Biotech Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Growth Rank falls into.


CHIX:DIMP
86GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Growth Rank of 7 as of Aug. 10, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sartorius Stedim Biotech and its competitors. This is 30% below median its historical median of 10.00. Over the past decade, Sartorius Stedim Biotech's Growth Rank has ranged from 6.00 to 10.00.
Is Sartorius Stedim Biotech's Growth Rank too high?
Sartorius Stedim Biotech's current Growth Rank of 7 is 30% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 10.00. Overall, Sartorius Stedim Biotech has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Growth Rank compare to ISRG and BDX?
Sartorius Stedim Biotech's Growth Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Sartorius Stedim Biotech's own Growth Rank has ranged from 6.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Growth Rank is 7, which is 30% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €201.36, compared to a current price of €172.65 — trading 14.3% below its estimated fair value. The current Growth Rank is 7, which is 30% below median its 10-year median of 10.00. Sartorius Stedim Biotech's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Growth Rank is 7 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €172.65 is trading 14.3% below its estimated GF Value™ of €201.36. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • Growth Rank: 7 (30% below median its 10-year median of 10.00)
  • GF Value™: €201.36 vs. price of €172.65 (14.3% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
86GF Score

Get the complete analysis for CHIX:DIMP

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€172.65
Price
€201.36
GF Value